Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
IPO Year: n/a
Exchange: NASDAQ
Website: trilliumtherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2021 | Buy → Hold | The Benchmark Company | |
| 11/17/2021 | Buy → Hold | Benchmark | |
| 8/24/2021 | $21.00 → $18.50 | Buy → Hold | Craig-Hallum |
| 8/24/2021 | Market Outperform → Market Perform | JMP Securities | |
| 8/23/2021 | $22.00 → $18.50 | Buy → Neutral | HC Wainwright & Co. |
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
4 - Trillium Therapeutics Inc. (0001616212) (Issuer)
The Benchmark Company downgraded Trillium Therapeutics from Buy to Hold
Benchmark downgraded Trillium Therapeutics from Buy to Hold
Craig-Hallum downgraded Trillium Therapeutics from Buy to Hold and set a new price target of $18.50 from $21.00 previously
JMP Securities downgraded Trillium Therapeutics from Market Outperform to Market Perform
HC Wainwright & Co. downgraded Trillium Therapeutics from Buy to Neutral and set a new price target of $18.50 from $22.00 previously
Benchmark initiated coverage of Trillium Therapeutics with a rating of Buy and set a new price target of $21.00
The Benchmark Company initiated coverage of Trillium Therapeutics with a rating of Buy and set a new price target of $21.00
15-12B - Trillium Therapeutics Inc. (0001616212) (Filer)
EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)
EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)
S-8 POS - Trillium Therapeutics Inc. (0001616212) (Filer)
POSASR - Trillium Therapeutics Inc. (0001616212) (Filer)
S-8 POS - Trillium Therapeutics Inc. (0001616212) (Filer)
POS AM - Trillium Therapeutics Inc. (0001616212) (Filer)
POS AM - Trillium Therapeutics Inc. (0001616212) (Filer)
8-K - Trillium Therapeutics Inc. (0001616212) (Filer)
25-NSE - Trillium Therapeutics Inc. (0001616212) (Subject)